Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011532 | 0.86 | MLNR (0.50) | MLNRMALT1TRPV1MAPTCYP3A4 | |
| SCHEMBL2009209 | 0.78 | KDM4E (0.48) | MLNRKDM4EMALT1MAPT | |
| SCHEMBL2006866 | 0.76 | MLNR (0.52) | MLNRMALT1 | |
| SCHEMBL27666132 | 0.76 | KDM4E (0.49) | MLNRKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2090447 | 0.73 | KDM4E (0.46) | MLNRKDM4EMAPTCYP1A2CYP3A4 | |
| SCHEMBL1803049 | 0.72 | KDM4E (0.66) | KDM4EMALT1 | |
| SCHEMBL13844240 | 0.72 | KDM4E (0.71) | MLNRKDM4ECYP3A4CYP2D6 | |
| SCHEMBL4733366 | 0.72 | MALT1 (0.46) | KDM4EMALT1 | |
| SCHEMBL5542326 | 0.71 | KDM4E (0.58) | MLNRKDM4EMAPTCYP1A2CYP3A4 | |
| SCHEMBL5542321 | 0.71 | KDM4E (0.58) | MLNRKDM4EMAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964602-B2 | Biaryl compounds useful as agonists of the Gpr38 receptor | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-1960390-B1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LTD (GB) | 2010-07-21 | — | — | EP | disclosed |
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GLAXO GROUP LIMITED | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GPR88, GPR68, GPBAR1 | MLNR 47/4885KDM4E 4600/4885MALT1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.